Ticagrelor

Apejuwe kukuru:

Orukọ API Itọkasi Sipesifikesonu US DMF EU DMF CEP
Ticagrelor Anticoagulant Ninu Ile Ọdun 28984  


Alaye ọja

ọja Tags

Apejuwe ọja

abẹlẹ

Ticagrelor jẹ alatako aramada ti olugba P2Y12 [1].

Ticagrelor ti ni ijabọ lati ṣe idiwọ awọn ipa prothrombotic ti ADP lori platelet lodi si olugba P2Y12.Ticagrelor ti ṣe afihan idinamọ pipe ti akopọ platelet ex vivo.Ni afikun Ticagrelor ti daba idinamọ-igbẹkẹle iwọn lilo ti akopọ platelet ninu eniyan.Yato si iwọnyi, Ticagrelor tun ti ṣe afihan ẹnu-ọna, ni itara, antagonist abuda iyipada.Ko dabi awọn inhibitors miiran, Ticagrelor tun ti royin lati dena olugba P2Y12 laisi iyipada ti iṣelọpọ.Yato si iyẹn, Ticagrelor jẹ aṣoju anti-platelet thienopyridine akọkọ ati ti iṣelọpọ nipasẹ CYP3A4 ati CYP2C19 [1] [2].

Awọn itọkasi:
[1] Zhou D1, Andersson TB, Grimm SW.Imọye inu vitro ti awọn ibaraenisepo oogun-oògùn ti o pọju pẹlu ticagrelor: cytochrome P450 phenotyping reaction, induction, induction, and different kinetics.Oògùn Metab Dispos.2011 Oṣu Kẹrin; 39 (4): 703-10.
[2] Li Y1, Landqvist C, Grimm SW.Iṣeduro ati iṣelọpọ agbara ticagrelor, aramada P2Y12 antagonist olugba olugba, ninu awọn eku, awọn eku, ati awọn marmosets.Oògùn Metab Dispos.Ọdun 2011 Oṣu Kẹsan; 39 (9): 1555-67.doi: 10.1124 / dmd.111.039669.Epub 2011 Oṣu Kẹta Ọjọ 13.

Apejuwe

Ticagrelor (AZD6140) jẹ antagonist olugba olugba P2Y12 ti o ni iyipada fun itọju akojọpọ platelet.

Ninu Vitro

Ticagrelor ṣe agbega idiwọ nla ti adenosine 5"diphosphate (ADP)itusilẹ Ca2 + ti o fa ni awọn platelets ti a fi silẹ la awọn alatako P2Y12R miiran.Ipa afikun ti ticagrelor ti o kọja P2Y12R antagonism jẹ ni apakan bi abajade ti ticagrelor ni idinamọ gbigbe gbigbe nucleoside deede 1 (ENT1) lori awọn platelets, eyiti o yori si ikojọpọ ti adenosine extracellular ati imuṣiṣẹ ti awọn olugba adenosine A2A ti Gs-papọ[1].Awọn sẹẹli B16-F10 ṣe afihan ibaraenisepo ti o dinku pẹlu awọn platelets lati awọn eku ti a ṣe itọju ticagrelor ni akawe si awọn eku ti a ṣe itọju iyọ[2].

Ni B16-F10 melanoma inu iṣọn-ẹjẹ ati awọn awoṣe metastasis intrasplenic, awọn eku ti a tọju pẹlu iwọn lilo ile-iwosan ti ticagrelor (10 mg / kg) ṣe afihan awọn idinku ti a samisi ninu ẹdọfóró (84%) ati ẹdọ (86%) metastases.Pẹlupẹlu, itọju ticagrelor ṣe ilọsiwaju iwalaaye ni akawe si awọn ẹranko ti a ṣe itọju iyọ.Ipa ti o jọra ni a ṣe akiyesi ni awoṣe alakan igbaya 4T1, pẹlu idinku ninu ẹdọfóró (55%) ati ọra inu egungun (87%) awọn metastases ti o tẹle itọju ticagrelor[2].Isakoso ẹnu ẹyọkan ti ticagrelor (1-10 miligiramu/kg) fa ipa inhibitory ti o ni ibatan iwọn lilo lori akopọ platelet.Ticagrelor, ni iwọn lilo ti o ga julọ (10 miligiramu / kg) ṣe idiwọ ikojọpọ platelet ni pataki ni wakati 1 lẹhin iwọn lilo ati pe a ṣe akiyesi idinamọ giga ni awọn wakati 4 lẹhin iwọn lilo.

Ibi ipamọ

4°C, aabo lati ina, ti o ti fipamọ labẹ nitrogen

* Ninu epo: -80°C, oṣu mẹfa;-20°C, oṣu kan (dabobo lati ina, ti o fipamọ labẹ nitrogen)

Ilana kemikali

Ticagrelor

Ijẹrisi

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

Ìṣàkóso didara

Quality management1

Igbero18Awọn iṣẹ akanṣe Igbelewọn Iṣeduro Didara eyiti o ti fọwọsi4, ati6ise agbese ni o wa labẹ alakosile.

Quality management2

Eto iṣakoso didara agbaye ti ilọsiwaju ti fi ipilẹ to lagbara fun tita.

Quality management3

Abojuto didara n ṣiṣẹ nipasẹ gbogbo igbesi aye ọja lati rii daju didara ati ipa itọju ailera.

Quality management4

Ẹgbẹ Aṣoju Iṣeduro Ọjọgbọn ṣe atilẹyin awọn ibeere didara lakoko ohun elo ati iforukọsilẹ.

gbóògì isakoso

cpf5
cpf6

Koria Countec Bottled Packaging Line

cpf7
cpf8

Taiwan CVC Laini Iṣakojọpọ Igo

cpf9
cpf10

Italy CAM Board Packaging Line

cpf11

German Fette Compacting Machine

cpf12

Japan Viswill Tablet Oluwari

cpf14-1

DCS Iṣakoso yara

ALÁGBẸ́NI

International ifowosowopo
International cooperation
Abele ifowosowopo
Domestic cooperation

  • Ti tẹlẹ:
  • Itele:

  • Kọ ifiranṣẹ rẹ nibi ki o si fi si wa